Today: 30 June 2026
CrowdStrike stock drops 3% to $453 as 2026 begins — here’s what investors are watching next
3 January 2026
1 min read

CrowdStrike stock drops 3% to $453 as 2026 begins — here’s what investors are watching next

NEW YORK, Jan 3, 2026, 11:38 ET — Market closed

  • CrowdStrike (CRWD) fell in the first trading session of 2026, lagging a modestly firmer U.S. stock market.
  • Cybersecurity peers also slipped, pointing to sector-wide pressure rather than a single headline.
  • Next catalysts: key U.S. data next week and CrowdStrike’s upcoming earnings timeline.

CrowdStrike Holdings, Inc. shares fell 3.2% on Friday, the first trading day of 2026, closing at $453.58 — down about $15 on the day. The stock traded between $449.49 and $477.25, with roughly 3.3 million shares changing hands.

The move matters because investors are starting the year trimming exposure to high-valuation software names — shares priced at rich multiples of sales — that often swing harder when interest-rate expectations shift.

Rates are back in the frame. “There may be a scenario where the Federal Reserve does not end up cutting rates in 2026,” Alex Guiliano, chief investment strategist at Resonate Wealth Partners, said in a Reuters interview. Reuters

CrowdStrike’s slide came even as broader U.S. stocks edged higher on Friday. The S&P 500 rose about 0.2%, while the Nasdaq Composite was little changed, according to the Associated Press.

Other cybersecurity names also slipped. Palo Alto Networks fell 2.6% and Fortinet lost 1.9% on Friday, MarketWatch data showed, pointing to soft demand for the group even with the broader tape steady.

For CrowdStrike, the last major company catalyst came in early December, when the Austin, Texas-based firm forecast fourth-quarter revenue of $1.29 billion to $1.30 billion and raised its full-year revenue outlook, citing growing adoption of AI across its product suite.

That keeps the spotlight on whether CrowdStrike can sustain growth while defending its valuation premium. Investors will watch subscription momentum, including annual recurring revenue — the yearly value of contracted subscription sales — and free cash flow, cash left after expenses and capital spending.

CrowdStrike has not announced the date for its next earnings report; Zacks Investment Research currently expects results around March 3.

Before Monday’s open, traders will take their cue from fresh U.S. data. The Institute for Supply Management is set to publish its manufacturing PMI at 10 a.m. ET on Jan. 5 and its services PMI at 10 a.m. ET on Jan. 7; PMI is a monthly survey that signals expansion when above 50 and contraction when below.

The week also brings the U.S. employment report for December 2025 on Jan. 9 at 8:30 a.m. ET, the Bureau of Labor Statistics calendar shows. The agency cautioned that release dates are subject to change due to a lapse in government services.

Technically, Friday’s low near $450 is a near-term level to watch. On the upside, the $475–$480 area marks the latest resistance — a zone where the stock recently struggled to push higher.

Until CrowdStrike delivers its next update on demand and guidance, traders are likely to treat CRWD as a high-beta cybersecurity name tied to rate expectations and broader software sentiment, alongside moves in peers such as Palo Alto and Fortinet.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • SELLAS Life Sciences (NASDAQ:SLS) Drops 7.77% After 8-K Filing Ahead of REGAL Data
    June 30, 2026, 10:28 AM EDT. SELLAS Life Sciences shares dropped 7.77% to $14.25 on Tuesday after an 8-K showing senior management agreements and as the market waits for Phase 3 REGAL data on galinpepimut-S in AML. The study is approaching a milestone with 78 of 80 survival events, making some investors cautious. The stock recently hit a 52-week high of $15.67, but resistance is holding there with support at the 20-day simple moving average around $8.87. Technicals are flashing overbought with the RSI at 85.19, which could mean sharper pullbacks. SELLAS works on cancer therapies including GPS and CDK9 drugs, tying its shares to updates around leadership moves and clinical trials.
Chevron stock today: CVX steadies near $152 as oil logs steepest annual drop since 2020
Previous Story

Chevron stock today: CVX steadies near $152 as oil logs steepest annual drop since 2020

Hyperscale Data (GPUS) stock jumps 20% in premarket as insider buying keeps spotlight on the microcap
Next Story

Hyperscale Data (GPUS) stock jumps 20% in premarket as insider buying keeps spotlight on the microcap

Go toTop